LOGIN  |  REGISTER
Terns Pharmaceuticals
Cue Biopharma

Phibro Animal Health Announces National Launch of Restoris™ Piezoelectric Dental Gel for Dogs

October 30, 2025 | Last Trade: US$41.86 0.67 1.63

TEANECK, N.J. / Oct 30, 2025 / Business Wire / Phibro Animal Health Corporation is proud to announce the national launch of Restoris™ piezoelectric dental gel, a revolutionary dental gel designed to treat and support long-term oral health in dogs with periodontal disease. Developed in collaboration with a leading U.S. dental school and licensed to Phibro, Restoris represents a breakthrough in veterinary dental care, offering a dual mechanism of action to restore oral health at its foundation.

The launch of Restoris builds on our recently announced license agreement for a novel therapeutic product targeting periodontal health in companion animals through a different mechanism of action. Together, these products form the foundation of a portfolio of assets in this exciting therapeutic area.

Periodontal disease is the most common clinical condition affecting adult dogs, with studies showing that 80–90% of dogs over the age of three have some component of periodontal disease. The disease is often invisible to pet owners, as it begins beneath the gumline and progresses silently until advanced stages. Untreated, periodontal disease can lead to chronic pain, infection, and tooth loss, and has been linked to systemic health problems including heart, kidney, and liver disease.

Restoris is applied directly into periodontal pockets using a prefilled syringe and then cured with supplied UV light. The gel’s piezoelectric particles generate microcurrents that stimulate bone-forming osteoblast cells, promoting new bone growth and reducing periodontal pocket depth. This innovative approach supports the natural healing response of periodontal tissues and helps restore healthy tooth attachment. Restoris has demonstrated efficacy in laboratory and clinical studies, showing significant reductions in periodontal pocket depth and generating alveolar bone around the affected tooth 30 days following treatment. This dual mechanism of action helps to re-establish periodontal integrity and support long-term oral health.

“We are excited to introduce Restoris to veterinarians and pet owners nationwide. At Phibro, our mission is to deliver innovative solutions that improve animal health and well-being. Restoris is a testament to our commitment to advancing veterinary medicine and supporting the lifelong health of companion animals,” said Jack C. Bendheim, Chairman, President, and Chief Executive Officer of Phibro Animal Health Corporation.

Restoris is now available for pre-order from Patterson Veterinary Supply and will ship within the next 30 days.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation (Nasdaq: PAHC) is a diversified global developer, manufacturer, and supplier of a broad range of animal health and mineral nutrition products. With a commitment to safe and effective solutions for our customers’ unique challenges, Phibro optimizes animal health and nutrition for better lives and a more sustainable world. Learn more at www.pahc.com.

C4 Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page